Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients

Sukh Singh; S. J. Langley; C. M. Houghton; S. D. Singh

doi:10.1159/000083691

Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients

Sukh Singh, S. J. Langley, C. M. Houghton, S. D. Singh

Research output: Contribution to journal › Article › peer-review

Abstract

In this double-blind, placebo-controlled, crossover study we compared the bronchoprotective effects of formoterol 12 μg inhaled via an HFA-134a inhaler (Modulite® HFA) versus a CFC and a DPI device in 38 patients with mildto-moderate persistent asthma. All three formoterol preparations significantly increased methacholine PD20 and FEV1 and improved small airway function parameters compared with placebo (p <0.001). No significant differences were observed between formoterol formulations. In conclusion, Modulite® HFA formoterol was found to be an effective and well tolerated treatment in patients with asthma, with comparable efficacy to current formoterol preparations. Copyright © 2005 S. Karger AG.

Original language	English
Pages (from-to)	35-37
Number of pages	2
Journal	Respiration
Volume	72
Issue number	1
DOIs	https://doi.org/10.1159/000083691
Publication status	Published - 2005

Keywords

Asthma
Bronchodilation
Bronchoprotection
Dry powder inhalers
Formoterol
Hydrofluoroalkanes
Pressurized metered-dose inhalers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000083691

Cite this

@article{b5895894207e4757a1f11e5d224a1877,

title = "Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients",

abstract = "In this double-blind, placebo-controlled, crossover study we compared the bronchoprotective effects of formoterol 12 μg inhaled via an HFA-134a inhaler (Modulite{\textregistered} HFA) versus a CFC and a DPI device in 38 patients with mildto-moderate persistent asthma. All three formoterol preparations significantly increased methacholine PD20 and FEV1 and improved small airway function parameters compared with placebo (p <0.001). No significant differences were observed between formoterol formulations. In conclusion, Modulite{\textregistered} HFA formoterol was found to be an effective and well tolerated treatment in patients with asthma, with comparable efficacy to current formoterol preparations. Copyright {\textcopyright} 2005 S. Karger AG.",

keywords = "Asthma, Bronchodilation, Bronchoprotection, Dry powder inhalers, Formoterol, Hydrofluoroalkanes, Pressurized metered-dose inhalers",

author = "Sukh Singh and Langley, {S. J.} and Houghton, {C. M.} and Singh, {S. D.}",

year = "2005",

doi = "10.1159/000083691",

language = "English",

volume = "72",

pages = "35--37",

journal = "Respiration",

issn = "0025-7931",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients

AU - Singh, Sukh

AU - Langley, S. J.

AU - Houghton, C. M.

AU - Singh, S. D.

PY - 2005

Y1 - 2005

N2 - In this double-blind, placebo-controlled, crossover study we compared the bronchoprotective effects of formoterol 12 μg inhaled via an HFA-134a inhaler (Modulite® HFA) versus a CFC and a DPI device in 38 patients with mildto-moderate persistent asthma. All three formoterol preparations significantly increased methacholine PD20 and FEV1 and improved small airway function parameters compared with placebo (p <0.001). No significant differences were observed between formoterol formulations. In conclusion, Modulite® HFA formoterol was found to be an effective and well tolerated treatment in patients with asthma, with comparable efficacy to current formoterol preparations. Copyright © 2005 S. Karger AG.

AB - In this double-blind, placebo-controlled, crossover study we compared the bronchoprotective effects of formoterol 12 μg inhaled via an HFA-134a inhaler (Modulite® HFA) versus a CFC and a DPI device in 38 patients with mildto-moderate persistent asthma. All three formoterol preparations significantly increased methacholine PD20 and FEV1 and improved small airway function parameters compared with placebo (p <0.001). No significant differences were observed between formoterol formulations. In conclusion, Modulite® HFA formoterol was found to be an effective and well tolerated treatment in patients with asthma, with comparable efficacy to current formoterol preparations. Copyright © 2005 S. Karger AG.

KW - Asthma

KW - Bronchodilation

KW - Bronchoprotection

KW - Dry powder inhalers

KW - Formoterol

KW - Hydrofluoroalkanes

KW - Pressurized metered-dose inhalers

U2 - 10.1159/000083691

DO - 10.1159/000083691

M3 - Article

SN - 0025-7931

VL - 72

SP - 35

EP - 37

JO - Respiration

JF - Respiration

IS - 1

ER -

Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this